Loading...
•
Jun 30, 2021
Precigen Q2 2021 Earnings Report
Precigen's financial performance for Q2 2021 was reported, highlighting increased revenues and R&D expenses.
Key Takeaways
Precigen reported an increase in total revenues by $3.2 million, driven by product and service revenues from Trans Ova and Exemplar. The company experienced an increase in research and development expenses, and a net loss from continuing operations of $20.1 million.
Total revenues increased by $3.2 million, or 10%, compared to the prior year period.
Research and development expenses increased by $4.2 million, or 44%, over the quarter ended June 30, 2020.
Net loss from continuing operations was $20.1 million, or $(0.10) per basic share.
Product and service revenues generated by Trans Ova and Exemplar increased $7.2 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...